Orca Bio’s T-cell immunotherapy candidate for blood cancers has more than doubled the number of patients surviving free of moderate-to-severe chronic graft versus host disease (GvHD). The Phase ...

Orca-T is composed of highly purified regulatory T-cells, CD34+ stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors.

Orca's cell therapy trounces traditional care in blood cancer phase 3, swimming into space's 'holy grail' By Gabrielle Masson Mar 17, 2025 7:00am ...

Orca-T, an investigational allogeneic T-cell immunotherapy, improved chronic graft-vs-host disease (cGVHD)–free survival compared with allogeneic stem cell transplant (allo-HSCT) in patients ...

Orca Bio targets blood cancer treatment approval next year. expand. Orca Bio co-founder and CEO Ivan Dimov. LiPo Ching | San Francisco Business Times. By Ron Leuty – Senior Reporter, ...

Orca Bio’s T-cell immunotherapy candidate for blood cancers has more than doubled the number of patients surviving free of moderate-to-severe chronic graft versus host disease (GvHD).